Clinical Trials Directory

Trials / Completed

CompletedNCT02370121

Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
24 (actual)
Sponsor
University of Guadalajara · Academic / Other
Sex
All
Age
30 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Gymnema sylvestre has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Gymnema sylvestre has an excellent potential for the prevention and treatment of metabolic syndrome.

Detailed description

A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with a diagnosis of metabolic syndrome in accordance with the modify International Diabetes Federation criteria. The patients received 300 mg capsules of Gymnema sylvestre or placebo, two times daily before breakfast and dinner for 90 days. Before and after intervention the investigators evaluated: The components of metabolic syndrome (waist circumference, triglycerides, high-density lipoprotein, fasting glucose and blood pressure), body weight, body mass index, total cholesterol, low-density lipoprotein, very-low-density lipoprotein, creatinine, aspartate transaminase and alanine transaminase. Were calculated: Areas under the curve of glucose and insulin were calculated with de Trapezoidal formula. Total insulin secretion was evaluated with the Insulinogenic index and the insulin sensitivity was estimated using the Matsuda index.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboCapsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
DRUGGymnema SylvestreCapsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.

Timeline

Start date
2013-02-01
Primary completion
2014-12-01
Completion
2015-01-01
First posted
2015-02-24
Last updated
2019-06-18
Results posted
2016-06-03

Source: ClinicalTrials.gov record NCT02370121. Inclusion in this directory is not an endorsement.